WO1996040281A2 - Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients - Google Patents
Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients Download PDFInfo
- Publication number
- WO1996040281A2 WO1996040281A2 PCT/US1996/009068 US9609068W WO9640281A2 WO 1996040281 A2 WO1996040281 A2 WO 1996040281A2 US 9609068 W US9609068 W US 9609068W WO 9640281 A2 WO9640281 A2 WO 9640281A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gas
- surfactant
- ocf
- group
- emulsion
- Prior art date
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 91
- 150000002170 ethers Chemical class 0.000 title description 10
- 229920001774 Perfluoroether Polymers 0.000 claims abstract description 31
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 238000002595 magnetic resonance imaging Methods 0.000 claims abstract description 5
- 239000007789 gas Substances 0.000 claims description 255
- 239000004094 surface-active agent Substances 0.000 claims description 126
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 59
- 150000003904 phospholipids Chemical class 0.000 claims description 42
- 239000000463 material Substances 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 33
- 239000007921 spray Substances 0.000 claims description 29
- -1 lysophospholipids Substances 0.000 claims description 28
- 238000002604 ultrasonography Methods 0.000 claims description 28
- 239000004005 microsphere Substances 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 229920002472 Starch Polymers 0.000 claims description 20
- 125000002252 acyl group Chemical group 0.000 claims description 20
- 238000003384 imaging method Methods 0.000 claims description 20
- 235000019698 starch Nutrition 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 239000002872 contrast media Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 13
- 239000000194 fatty acid Substances 0.000 claims description 13
- 229930195729 fatty acid Natural products 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 11
- 230000007935 neutral effect Effects 0.000 claims description 10
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- 239000011800 void material Substances 0.000 claims description 8
- 239000003945 anionic surfactant Substances 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 125000000129 anionic group Chemical group 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000002736 nonionic surfactant Substances 0.000 claims description 5
- 125000002525 phosphocholine group Chemical class OP(=O)(OCC[N+](C)(C)C)O* 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 235000021552 granulated sugar Nutrition 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- OYAUGTZMGLUNPS-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoro-2-(1,1,1,2,3,3,3-heptafluoropropan-2-yloxy)propane Chemical class FC(F)(F)C(F)(C(F)(F)F)OC(F)(C(F)(F)F)C(F)(F)F OYAUGTZMGLUNPS-UHFFFAOYSA-N 0.000 claims 3
- 239000008176 lyophilized powder Substances 0.000 claims 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 22
- YSGKVOMJRCQYMT-UHFFFAOYSA-N 1,1,2,2-tetrafluoro-1-[1,1,2,2-tetrafluoro-2-(trifluoromethoxy)ethoxy]-2-(trifluoromethoxy)ethane Chemical compound FC(F)(F)OC(F)(F)C(F)(F)OC(F)(F)C(F)(F)OC(F)(F)F YSGKVOMJRCQYMT-UHFFFAOYSA-N 0.000 abstract description 18
- 238000012285 ultrasound imaging Methods 0.000 abstract description 9
- JTPMOHUDFCBCEC-UHFFFAOYSA-N 1,1,2,2-tetrafluoro-1,2-bis(trifluoromethoxy)ethane Chemical compound FC(F)(F)OC(F)(F)C(F)(F)OC(F)(F)F JTPMOHUDFCBCEC-UHFFFAOYSA-N 0.000 abstract description 4
- XZKOELJOFVHXRS-UHFFFAOYSA-N 1,1,1,2,2,3,3-heptafluoro-3-(1,1,2,2,3,3,3-heptafluoropropoxy)propane Chemical compound FC(F)(F)C(F)(F)C(F)(F)OC(F)(F)C(F)(F)C(F)(F)F XZKOELJOFVHXRS-UHFFFAOYSA-N 0.000 abstract description 2
- 230000005923 long-lasting effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 55
- 239000002357 osmotic agent Substances 0.000 description 43
- 239000000843 powder Substances 0.000 description 35
- 239000003795 chemical substances by application Substances 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 16
- 239000006185 dispersion Substances 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 13
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 13
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 229960004624 perflexane Drugs 0.000 description 12
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000011049 filling Methods 0.000 description 11
- 229940050526 hydroxyethylstarch Drugs 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 239000003607 modifier Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 10
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 230000003204 osmotic effect Effects 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- UJMWVICAENGCRF-UHFFFAOYSA-N oxygen difluoride Chemical compound FOF UJMWVICAENGCRF-UHFFFAOYSA-N 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 8
- 238000000527 sonication Methods 0.000 description 8
- 238000001694 spray drying Methods 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 229920001993 poloxamer 188 Polymers 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 6
- 150000002829 nitrogen Chemical class 0.000 description 6
- 229950003332 perflubutane Drugs 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 5
- 239000010441 alabaster Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 description 5
- 235000019800 disodium phosphate Nutrition 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 5
- 229920000570 polyether Polymers 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000010702 perfluoropolyether Substances 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229940044519 poloxamer 188 Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000881 depressing effect Effects 0.000 description 3
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000005865 ionizing radiation Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229960004692 perflenapent Drugs 0.000 description 3
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011555 rabbit model Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 235000014036 Castanea Nutrition 0.000 description 2
- 241001070941 Castanea Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- NVANJYGRGNEULT-BDZGGURLSA-N [(3s,4r,5r)-4-hexadecanoyloxy-5-[(1r)-1-hexadecanoyloxy-2-hydroxyethyl]oxolan-3-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCCCCCC NVANJYGRGNEULT-BDZGGURLSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 229940039231 contrast media Drugs 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical class FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RMHCWMIZBMGHKV-UHFFFAOYSA-N 1,1,2,3,3,4,4,5,5,6,6,6-dodecafluorohex-1-ene Chemical compound FC(F)=C(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RMHCWMIZBMGHKV-UHFFFAOYSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000264877 Hippospongia communis Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 238000001016 Ostwald ripening Methods 0.000 description 1
- 229910018152 SeF6 Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- PZQBWGFCGIRLBB-NJYHNNHUSA-N [(2r)-2-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1O PZQBWGFCGIRLBB-NJYHNNHUSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- DPYMFVXJLLWWEU-UHFFFAOYSA-N desflurane Chemical compound FC(F)OC(F)C(F)(F)F DPYMFVXJLLWWEU-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229940064366 hespan Drugs 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 150000002835 noble gases Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 229960004065 perflutren Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- LMDVZDMBPZVAIV-UHFFFAOYSA-N selenium hexafluoride Chemical compound F[Se](F)(F)(F)(F)F LMDVZDMBPZVAIV-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acoustics & Sound (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Colloid Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT96918164T ATE216894T1 (en) | 1995-06-07 | 1996-06-05 | GAS EMULSIONS STABILIZED BY FLUORINATED ETHERS WITH LOW OSTWALD COEFFICIENTS |
DE69621015T DE69621015T2 (en) | 1995-06-07 | 1996-06-05 | GAS EMULSIONS STABILIZED BY FLUORINE ETHERS WITH LOW EAST FOREST COEFFICIENTS |
EP96918164A EP0833669B1 (en) | 1995-06-07 | 1996-06-05 | Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients |
PL96323868A PL185883B1 (en) | 1995-06-07 | 1996-06-05 | Emulsions of gases stabilise by means of fluorinated ethers of low ostwald coefficient |
DK96918164T DK0833669T3 (en) | 1995-06-07 | 1996-06-05 | Gas emulsions stabilized with fluorinated ethers with low Ostwald coefficients |
IL13534296A IL135342A0 (en) | 1995-06-07 | 1996-06-05 | A microbubble precursor |
AU60487/96A AU712946B2 (en) | 1995-06-07 | 1996-06-05 | Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients |
IL12221796A IL122217A (en) | 1995-06-07 | 1996-06-05 | Gas emulsions for ultrasound contrast enhancement stabilized with fluorinated ethers |
JP50147797A JP4067116B2 (en) | 1995-06-07 | 1996-06-05 | Gas emulsion stabilized with fluorinated ether with low Ostwald coefficient |
US08/973,281 US6193952B1 (en) | 1995-06-07 | 1996-06-05 | Stabilized gas emulsions containing phospholipid for ultrasound contrast enhancement |
NO975317A NO975317L (en) | 1995-06-07 | 1997-11-19 | Gas emulsions stabilized with fluorinated ethers with low cheese forest coefficients |
US09/746,215 US20020119102A1 (en) | 1996-06-05 | 2000-12-22 | Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/479,621 | 1995-06-07 | ||
US08/479,621 US5804162A (en) | 1995-06-07 | 1995-06-07 | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/479,621 Continuation-In-Part US5804162A (en) | 1995-06-07 | 1995-06-07 | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/973,281 Continuation US6193952B1 (en) | 1995-06-07 | 1996-06-05 | Stabilized gas emulsions containing phospholipid for ultrasound contrast enhancement |
US08/973,281 A-371-Of-International US6193952B1 (en) | 1995-06-07 | 1996-06-05 | Stabilized gas emulsions containing phospholipid for ultrasound contrast enhancement |
US09/746,215 Continuation US20020119102A1 (en) | 1995-06-07 | 2000-12-22 | Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients |
Publications (4)
Publication Number | Publication Date |
---|---|
WO1996040281A2 true WO1996040281A2 (en) | 1996-12-19 |
WO1996040281A9 WO1996040281A9 (en) | 1997-02-06 |
WO1996040281A3 WO1996040281A3 (en) | 1997-03-13 |
WO1996040281B1 WO1996040281B1 (en) | 2001-04-05 |
Family
ID=23904745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/009068 WO1996040281A2 (en) | 1995-06-07 | 1996-06-05 | Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients |
Country Status (18)
Country | Link |
---|---|
US (2) | US5804162A (en) |
EP (2) | EP1174153B1 (en) |
JP (1) | JP4067116B2 (en) |
KR (1) | KR100401429B1 (en) |
CN (1) | CN1087954C (en) |
AT (2) | ATE337018T1 (en) |
AU (1) | AU712946B2 (en) |
CA (1) | CA2222186A1 (en) |
CZ (1) | CZ391397A3 (en) |
DE (2) | DE69621015T2 (en) |
DK (1) | DK0833669T3 (en) |
ES (2) | ES2176462T3 (en) |
HU (1) | HUP9900848A3 (en) |
IL (1) | IL122217A (en) |
NO (1) | NO975317L (en) |
PL (1) | PL185883B1 (en) |
PT (1) | PT833669E (en) |
WO (1) | WO1996040281A2 (en) |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998017324A2 (en) * | 1996-10-21 | 1998-04-30 | Marsden, John, Christopher | Improvements in or relating to contrast agents |
WO1999047538A1 (en) | 1998-03-19 | 1999-09-23 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
EP1001816A1 (en) * | 1996-11-25 | 2000-05-24 | Imarx Pharmaceutical Corp. | Perfluorinated-ether compositions as diagnostic contrast agents |
WO2002064612A2 (en) | 2001-02-09 | 2002-08-22 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
WO2005077042A2 (en) | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1683865A2 (en) | 2001-02-02 | 2006-07-26 | Eli Lilly & Company | Mammalian proteins and in particular CD200 |
WO2007056352A2 (en) | 2005-11-07 | 2007-05-18 | The Scripps Research Institute | Compositions and methods for controlling tissue factor signaling specificity |
WO2008105797A2 (en) | 2006-06-30 | 2008-09-04 | Bristol-Myers Squibb Company | Polynucleotides encoding novel pcsk9 variants |
EP1997829A1 (en) | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2075346A2 (en) | 2002-01-08 | 2009-07-01 | Novartis Vaccines and Diagnostics, Inc. | Gene products differentially expressed in cancerous breast cells and their methods of use |
WO2009118300A1 (en) | 2008-03-25 | 2009-10-01 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2228389A2 (en) | 2001-04-13 | 2010-09-15 | Human Genome Sciences, Inc. | Antibodies against vascular endothelial growth factor 2 |
EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
EP2266628A2 (en) | 2003-05-13 | 2010-12-29 | Novartis Vaccines and Diagnostics, Inc. | Method of determining the susceptibility to bone meatastases by EPhA2 expression |
EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
WO2011036118A1 (en) | 2009-09-22 | 2011-03-31 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
WO2011051392A1 (en) | 2009-10-30 | 2011-05-05 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and cancer |
US7943134B2 (en) | 2005-08-31 | 2011-05-17 | Academia Sinica | Compositions and methods for identifying response targets and treating flavivirus infection responses |
EP2357192A1 (en) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
WO2011107586A1 (en) | 2010-03-05 | 2011-09-09 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, | Smoc1, tenascin-c and brain cancers |
WO2011131611A1 (en) | 2010-04-19 | 2011-10-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
WO2011154485A1 (en) | 2010-06-10 | 2011-12-15 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
WO2012032143A1 (en) | 2010-09-10 | 2012-03-15 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
EP2431054A2 (en) | 2000-06-15 | 2012-03-21 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
US8221983B2 (en) | 2000-06-02 | 2012-07-17 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
WO2012168259A1 (en) | 2011-06-06 | 2012-12-13 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
WO2013068431A1 (en) | 2011-11-08 | 2013-05-16 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
WO2013068432A1 (en) | 2011-11-08 | 2013-05-16 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
WO2013102825A1 (en) | 2012-01-02 | 2013-07-11 | Novartis Ag | Cdcp1 and breast cancer |
WO2013144240A1 (en) | 2012-03-29 | 2013-10-03 | Friedrich Miescher Institute For Biomedical Research | Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer |
WO2014001482A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research | Treating diseases by modulating a specific isoform of mkl1 |
WO2014006114A1 (en) | 2012-07-05 | 2014-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
WO2014006115A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
WO2015019286A1 (en) | 2013-08-07 | 2015-02-12 | Friedrich Miescher Institute For Biomedical Research | New screening method for the treatment friedreich's ataxia |
WO2015189816A1 (en) | 2014-06-13 | 2015-12-17 | Friedrich Miescher Institute For Biomedical Research | New treatment against influenza virus |
WO2015198202A1 (en) | 2014-06-23 | 2015-12-30 | Friedrich Miescher Institute For Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas |
WO2016001830A1 (en) | 2014-07-01 | 2016-01-07 | Friedrich Miescher Institute For Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
WO2016046768A1 (en) | 2014-09-24 | 2016-03-31 | Friedrich Miescher Institute For Biomedical Research | Lats and breast cancer |
EP3037544A1 (en) | 2005-10-13 | 2016-06-29 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases |
US9427396B2 (en) | 2008-06-27 | 2016-08-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
US9545457B2 (en) | 1998-01-14 | 2017-01-17 | Lantheus Medical Imaging, Inc. | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
EP3117833A1 (en) | 2005-07-19 | 2017-01-18 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by lif |
WO2017072669A1 (en) | 2015-10-28 | 2017-05-04 | Friedrich Miescher Institute For Biomedical Research | Tenascin-w and biliary tract cancers |
US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
US10022460B2 (en) | 2014-12-31 | 2018-07-17 | Lantheus Medical Imaging, Inc. | Lipid-encapsulated gas microsphere compositions and related methods |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
WO2019213660A2 (en) | 2018-05-04 | 2019-11-07 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
US10588988B2 (en) | 2016-05-04 | 2020-03-17 | Lantheus Medical Imaging, Inc. | Methods and devices for preparation of ultrasound contrast agents |
WO2020077236A1 (en) | 2018-10-12 | 2020-04-16 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
WO2020172343A2 (en) | 2019-02-19 | 2020-08-27 | Massachusetts Institute Of Technology | Methods for treating injuries |
WO2020186235A1 (en) | 2019-03-14 | 2020-09-17 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
WO2020191079A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
WO2020191069A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Modulation of type 2 immunity by targeting clec-2 signaling |
WO2020243661A1 (en) | 2019-05-31 | 2020-12-03 | The Broad Institute, Inc. | Methods for treating metabolic disorders by targeting adcy5 |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
US11225689B2 (en) | 2016-08-17 | 2022-01-18 | The Broad Institute, Inc. | Method for determination and identification of cell signatures and cell markers |
US11680296B2 (en) | 2017-10-16 | 2023-06-20 | Massachusetts Institute Of Technology | Mycobacterium tuberculosis host-pathogen interaction |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
WO2024016003A2 (en) | 2022-07-14 | 2024-01-18 | The Broad Institute, Inc. | Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
DK0711179T3 (en) * | 1993-07-30 | 2005-02-14 | Imcor Pharmaceutical Co | Stabilized ultrasound microbubble compositions |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US5997898A (en) | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US5804162A (en) * | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
ATE345682T1 (en) | 1996-05-01 | 2006-12-15 | Imarx Pharmaceutical Corp | IN VITRO METHOD FOR INTRODUCING NUCLEIC ACIDS INTO A CELL |
IL128057A (en) * | 1996-08-05 | 2001-08-26 | Schering Ag | Process for the production of contrast media |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
DE69737915T2 (en) | 1996-09-11 | 2008-03-13 | Bristol-Myers Squibb Medical Imaging, Inc. | Method of diagnostic imaging of the kidney region using a contrast agent and a vasodilator |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US6270460B1 (en) * | 1999-06-24 | 2001-08-07 | Acuson Corporation | Apparatus and method to limit the life span of a diagnostic medical ultrasound probe |
US6849194B2 (en) | 2000-11-17 | 2005-02-01 | Pcbu Services, Inc. | Methods for preparing ethers, ether compositions, fluoroether fire extinguishing systems, mixtures and methods |
DE10119522A1 (en) * | 2001-04-20 | 2002-12-05 | Innovacell Biotechnologie Gmbh | Preparation and application of a suspension composition with an ultrasound contrast medium |
US7300743B2 (en) * | 2003-03-06 | 2007-11-27 | E. I. Du Pont De Nemours And Company | Radiation durable organic compounds with high transparency in the vacuum ultraviolet, and method for preparing |
US20050074406A1 (en) * | 2003-10-03 | 2005-04-07 | Scimed Life Systems, Inc. | Ultrasound coating for enhancing visualization of medical device in ultrasound images |
US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
CA2723171C (en) * | 2008-05-02 | 2018-03-27 | Celsense, Inc. | Emulsion compositions and methods for nuclear magnetic resonance and other imaging |
US20100160576A1 (en) * | 2008-11-21 | 2010-06-24 | University Of Tennessee Research Foundation | Perfluorinated poly(oxymethylene) compounds |
JP2013180956A (en) * | 2012-02-29 | 2013-09-12 | Sunstar Engineering Inc | Bactericidal agent composition |
CN104353088A (en) * | 2014-09-30 | 2015-02-18 | 东南大学 | Preparation method of lipid bubbles |
US10052394B2 (en) | 2014-11-21 | 2018-08-21 | General Electric Company | Microbubble tether for diagnostic and therapeutic applications |
EP3176206A1 (en) * | 2015-12-01 | 2017-06-07 | Evonik Degussa GmbH | Method for the preparation of fine cell foams using a cell aging inhibitor |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0052575A2 (en) * | 1980-11-17 | 1982-05-26 | Schering Aktiengesellschaft | Composition generating microbubbles |
WO1993005819A1 (en) * | 1991-09-17 | 1993-04-01 | Sonus Pharmaceuticals, Inc | Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media |
WO1994009703A1 (en) * | 1992-11-02 | 1994-05-11 | Drexel University | Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same |
WO1994021301A1 (en) * | 1993-03-16 | 1994-09-29 | Holmes, Michael, John | Improvements in or relating to contrast agents |
WO1994028939A1 (en) * | 1993-06-04 | 1994-12-22 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
DE4406474A1 (en) * | 1994-02-23 | 1995-08-24 | Schering Ag | Gas-containing microparticles, agents containing them, their use in ultrasound diagnostics, and methods for producing the particles and agents |
WO1996009793A1 (en) * | 1994-09-28 | 1996-04-04 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
WO1996026746A1 (en) * | 1995-02-28 | 1996-09-06 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4276885A (en) * | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
US4657756A (en) * | 1980-11-17 | 1987-04-14 | Schering Aktiengesellschaft | Microbubble precursors and apparatus for their production and use |
DE3141641A1 (en) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | ULTRASONIC CONTRAST AGENTS AND THEIR PRODUCTION |
US4718433A (en) * | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
US4586511A (en) * | 1983-03-04 | 1986-05-06 | Children's Hospital Medical Center | Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance |
US5141738A (en) * | 1983-04-15 | 1992-08-25 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
DE3313947A1 (en) * | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS |
DE3324754A1 (en) * | 1983-07-06 | 1985-01-17 | Schering AG, 1000 Berlin und 4709 Bergkamen | ULTRASONIC CONTRASTING AGENTS AND THEIR PRODUCTION |
GB8504916D0 (en) * | 1985-02-26 | 1985-03-27 | Isc Chemicals Ltd | Emulsions of perfluorocarbons in aqueous media |
US5186922A (en) * | 1985-03-15 | 1993-02-16 | See/Shell Biotechnology, Inc. | Use of biodegradable microspheres labeled with imaging energy constrast materials |
US4613326A (en) * | 1985-07-12 | 1986-09-23 | Becton, Dickinson And Company | Two-component medication syringe assembly |
DE3529195A1 (en) * | 1985-08-14 | 1987-02-26 | Max Planck Gesellschaft | CONTRAST AGENTS FOR ULTRASONIC EXAMINATIONS AND METHOD FOR THE PRODUCTION THEREOF |
US4684479A (en) * | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
DE3688613T2 (en) * | 1985-11-18 | 1994-01-13 | Access Pharma Inc | POLYCHELING SUBSTANCES FOR IMAGING AND SPECTRAL INCREASING (AND SPECTRAL SHIFT). |
US4927623A (en) * | 1986-01-14 | 1990-05-22 | Alliance Pharmaceutical Corp. | Dissolution of gas in a fluorocarbon liquid |
GB8601100D0 (en) * | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
EP0231091B1 (en) * | 1986-01-24 | 1993-03-31 | Children's Hospital Medical Center | Stable emulsions of highly fluorinated organic compound |
US4925678A (en) * | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
US4781676A (en) * | 1987-02-20 | 1988-11-01 | Air Products And Chemicals, Inc. | Interstitial administration of perfluorochemical emulsions for reoxygenation of hypoxic tumor cells |
US5108759A (en) * | 1987-04-01 | 1992-04-28 | Ranney David F | Endothelial envelopment drug carriers |
DE3741201A1 (en) * | 1987-12-02 | 1989-06-15 | Schering Ag | ULTRASONIC PROCESS AND METHOD FOR IMPLEMENTING IT |
DE3741199A1 (en) * | 1987-12-02 | 1989-08-17 | Schering Ag | USE OF ULTRASONIC CONTRASTING AGENTS FOR ULTRASONIC LITHOTRIPSY |
US4844882A (en) * | 1987-12-29 | 1989-07-04 | Molecular Biosystems, Inc. | Concentrated stabilized microbubble-type ultrasonic imaging agent |
WO1989006978A1 (en) * | 1988-02-05 | 1989-08-10 | Schering Aktiengesellschaft Berlin Und Bergkamen | Ultrasonic contrast agents, process for producing them and their use as diagnostic and therapeutic agents |
US4898734A (en) * | 1988-02-29 | 1990-02-06 | Massachusetts Institute Of Technology | Polymer composite for controlled release or membrane formation |
US5171755A (en) * | 1988-04-29 | 1992-12-15 | Hemagen/Pfc | Emulsions of highly fluorinated organic compounds |
US4957656A (en) * | 1988-09-14 | 1990-09-18 | Molecular Biosystems, Inc. | Continuous sonication method for preparing protein encapsulated microbubbles |
US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5209720A (en) * | 1989-12-22 | 1993-05-11 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US5149319A (en) * | 1990-09-11 | 1992-09-22 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids |
US5228446A (en) * | 1989-12-22 | 1993-07-20 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5334381A (en) * | 1989-12-22 | 1994-08-02 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5305757A (en) * | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5123414A (en) * | 1989-12-22 | 1992-06-23 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
DE4004430A1 (en) * | 1990-02-09 | 1991-08-14 | Schering Ag | CONSTRUCTED POLYALDEHYDE CONSTITUENTS |
GB9003821D0 (en) * | 1990-02-20 | 1990-04-18 | Danbiosyst Uk | Diagnostic aid |
US5556610A (en) * | 1992-01-24 | 1996-09-17 | Bracco Research S.A. | Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method |
US5445813A (en) * | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
IN172208B (en) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
US5205287A (en) * | 1990-04-26 | 1993-04-27 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
GB9009423D0 (en) * | 1990-04-26 | 1990-06-20 | Williams Alun R | Assessment of vascular perfusion by the display of harmonic echoes from ultrasonically excited gas bubbles |
AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
US5315997A (en) * | 1990-06-19 | 1994-05-31 | Molecular Biosystems, Inc. | Method of magnetic resonance imaging using diamagnetic contrast |
JP2599492B2 (en) * | 1990-08-21 | 1997-04-09 | 第一製薬株式会社 | Manufacturing method of liposome preparation |
JP3247374B2 (en) * | 1990-10-05 | 2002-01-15 | ブラッコ インターナショナル ベスローテン フェンノートシャップ | A method for the production of stable suspensions of hollow gas-encapsulated microspheres suitable for ultrasound ecology |
DE4100470A1 (en) * | 1991-01-09 | 1992-07-16 | Byk Gulden Lomberg Chem Fab | Echo contrast agent |
US5370901A (en) * | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
EP0504881B2 (en) * | 1991-03-22 | 2000-11-08 | Katsuro Tachibana | Booster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same |
US5205290A (en) * | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
JP3319754B2 (en) * | 1991-06-03 | 2002-09-03 | ニユコメド・イメージング・アクシエセルカペト | Improvements in or on contrast agents |
ATE151993T1 (en) * | 1991-07-05 | 1997-05-15 | Nycomed Imaging As | IMPROVEMENTS TO CONTRAST AGENTS |
GB9116610D0 (en) * | 1991-08-01 | 1991-09-18 | Danbiosyst Uk | Preparation of microparticles |
WO1993003671A1 (en) * | 1991-08-13 | 1993-03-04 | Molecular Biosystem, Inc. | Method of mri imaging using diamagnetic contrast agents |
US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
MX9205298A (en) * | 1991-09-17 | 1993-05-01 | Steven Carl Quay | GASEOUS ULTRASOUND CONTRASTING MEDIA AND METHOD FOR SELECTING GASES TO BE USED AS ULTRASOUND CONTRASTING MEDIA |
WO1993006869A1 (en) * | 1991-10-04 | 1993-04-15 | Mallinckrodt Medical, Inc. | Gaseous ultrasound contrast agents |
US5304325A (en) * | 1991-11-13 | 1994-04-19 | Hemagen/Pfc | Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use |
US5196183A (en) * | 1991-12-04 | 1993-03-23 | Sterling Winthrop Inc. | Contrast agents for ultrasound imaging |
GB9200388D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
IL104084A (en) * | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them |
DE4219723A1 (en) * | 1992-06-13 | 1993-12-16 | Schering Ag | Microparticles, processes for their production and their use in diagnostics |
AU4563093A (en) * | 1992-07-03 | 1994-01-31 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Echographic contrast agent composition |
CA2144749A1 (en) * | 1992-09-16 | 1994-03-31 | Jo Klaveness | Improvements in or relating to contrast agents |
US5314644A (en) * | 1992-10-19 | 1994-05-24 | Virginia Polytechnic Institute And State University | Microbubble generator |
US5393527A (en) * | 1993-01-04 | 1995-02-28 | Becton, Dickinson And Company | Stabilized microspheres and methods of preparation |
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
WO1994016739A1 (en) * | 1993-01-25 | 1994-08-04 | Sonus Pharmaceuticals, Inc. | Phase shift colloids as ultrasound contrast agents |
DK0693924T4 (en) * | 1993-02-22 | 2008-08-04 | Abraxis Bioscience Inc | Process for (in vivo) delivery of biological materials and compositions suitable therefor |
US5333613A (en) * | 1993-03-23 | 1994-08-02 | Delineate | Microparticles as ultrasonic contrast media |
KR100295173B1 (en) * | 1993-12-15 | 2001-09-17 | 엔. 토모브 | Gas Mixtures Useful as Ultrasonic Contrast Media |
US5502094A (en) * | 1994-05-20 | 1996-03-26 | Minnesota Mining And Manufacturing Company | Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use |
US5562893A (en) * | 1994-08-02 | 1996-10-08 | Molecular Biosystems, Inc. | Gas-filled microspheres with fluorine-containing shells |
US5804162A (en) * | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
GB9808599D0 (en) * | 1998-04-22 | 1998-06-24 | Nycomed Imaging As | Improvements in or realting to contrast agents |
GB9808582D0 (en) * | 1998-04-22 | 1998-06-24 | Nycomed Imaging As | Improvements in or relating to contrast agents |
-
1995
- 1995-06-07 US US08/479,621 patent/US5804162A/en not_active Expired - Fee Related
-
1996
- 1996-06-05 DE DE69621015T patent/DE69621015T2/en not_active Expired - Fee Related
- 1996-06-05 CZ CZ973913A patent/CZ391397A3/en unknown
- 1996-06-05 AU AU60487/96A patent/AU712946B2/en not_active Ceased
- 1996-06-05 DK DK96918164T patent/DK0833669T3/en active
- 1996-06-05 DE DE69636486T patent/DE69636486T2/en not_active Expired - Fee Related
- 1996-06-05 EP EP01119824A patent/EP1174153B1/en not_active Expired - Lifetime
- 1996-06-05 PL PL96323868A patent/PL185883B1/en unknown
- 1996-06-05 AT AT01119824T patent/ATE337018T1/en not_active IP Right Cessation
- 1996-06-05 ES ES96918164T patent/ES2176462T3/en not_active Expired - Lifetime
- 1996-06-05 ES ES01119824T patent/ES2269262T3/en not_active Expired - Lifetime
- 1996-06-05 WO PCT/US1996/009068 patent/WO1996040281A2/en not_active Application Discontinuation
- 1996-06-05 HU HU9900848A patent/HUP9900848A3/en unknown
- 1996-06-05 KR KR1019970709075A patent/KR100401429B1/en not_active IP Right Cessation
- 1996-06-05 US US08/973,281 patent/US6193952B1/en not_active Expired - Fee Related
- 1996-06-05 AT AT96918164T patent/ATE216894T1/en not_active IP Right Cessation
- 1996-06-05 CA CA002222186A patent/CA2222186A1/en not_active Abandoned
- 1996-06-05 EP EP96918164A patent/EP0833669B1/en not_active Expired - Lifetime
- 1996-06-05 JP JP50147797A patent/JP4067116B2/en not_active Expired - Fee Related
- 1996-06-05 CN CN96195879A patent/CN1087954C/en not_active Expired - Fee Related
- 1996-06-05 IL IL12221796A patent/IL122217A/en not_active IP Right Cessation
- 1996-06-05 PT PT96918164T patent/PT833669E/en unknown
-
1997
- 1997-11-19 NO NO975317A patent/NO975317L/en not_active Application Discontinuation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0052575A2 (en) * | 1980-11-17 | 1982-05-26 | Schering Aktiengesellschaft | Composition generating microbubbles |
WO1993005819A1 (en) * | 1991-09-17 | 1993-04-01 | Sonus Pharmaceuticals, Inc | Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media |
WO1994009703A1 (en) * | 1992-11-02 | 1994-05-11 | Drexel University | Surfactant-stabilized microbubble mixtures, process for preparing and methods of using the same |
WO1994021301A1 (en) * | 1993-03-16 | 1994-09-29 | Holmes, Michael, John | Improvements in or relating to contrast agents |
WO1994028939A1 (en) * | 1993-06-04 | 1994-12-22 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
DE4406474A1 (en) * | 1994-02-23 | 1995-08-24 | Schering Ag | Gas-containing microparticles, agents containing them, their use in ultrasound diagnostics, and methods for producing the particles and agents |
WO1996009793A1 (en) * | 1994-09-28 | 1996-04-04 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
WO1996026746A1 (en) * | 1995-02-28 | 1996-09-06 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
Non-Patent Citations (1)
Title |
---|
LANGMUIR (1995), 11(8), 2966-74 CODEN: LANGD5;ISSN: 0743-7463, 1995, XP002019542 KABALNOV, ALEXEY ET AL: "Phospholipids as Emulsion Stabilizers. 1. Interfacial Tensions" * |
Cited By (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1264604A3 (en) * | 1996-10-21 | 2004-03-10 | Amersham Health AS | Improvements in or relating to contrast agents |
WO1998017324A3 (en) * | 1996-10-21 | 1998-06-25 | Marsden John Christopher | Improvements in or relating to contrast agents |
WO1998017324A2 (en) * | 1996-10-21 | 1998-04-30 | Marsden, John, Christopher | Improvements in or relating to contrast agents |
EP1264604A2 (en) * | 1996-10-21 | 2002-12-11 | Amersham Health AS | Improvements in or relating to contrast agents |
US6375931B2 (en) | 1996-10-21 | 2002-04-23 | Nycomed Imaging As | Contrast agents |
EP1001816A4 (en) * | 1996-11-25 | 2002-07-17 | Imarx Pharmaceutical Corp | Perfluorinated-ether compositions as diagnostic contrast agents |
EP1001816A1 (en) * | 1996-11-25 | 2000-05-24 | Imarx Pharmaceutical Corp. | Perfluorinated-ether compositions as diagnostic contrast agents |
US9545457B2 (en) | 1998-01-14 | 2017-01-17 | Lantheus Medical Imaging, Inc. | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
WO1999047538A1 (en) | 1998-03-19 | 1999-09-23 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
EP1982990A1 (en) | 1998-03-19 | 2008-10-22 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
EP2357192A1 (en) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8221983B2 (en) | 2000-06-02 | 2012-07-17 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
EP2431054A2 (en) | 2000-06-15 | 2012-03-21 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
EP1683865A2 (en) | 2001-02-02 | 2006-07-26 | Eli Lilly & Company | Mammalian proteins and in particular CD200 |
WO2002064612A2 (en) | 2001-02-09 | 2002-08-22 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
EP2228389A2 (en) | 2001-04-13 | 2010-09-15 | Human Genome Sciences, Inc. | Antibodies against vascular endothelial growth factor 2 |
EP2990417A1 (en) | 2001-12-21 | 2016-03-02 | Human Genome Sciences, Inc. | Albumin insulin fusion protein |
EP2261250A1 (en) | 2001-12-21 | 2010-12-15 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2277888A2 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Fusion proteins of albumin and erythropoietin |
EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2277889A2 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
EP1997829A1 (en) | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2075346A2 (en) | 2002-01-08 | 2009-07-01 | Novartis Vaccines and Diagnostics, Inc. | Gene products differentially expressed in cancerous breast cells and their methods of use |
EP2266628A2 (en) | 2003-05-13 | 2010-12-29 | Novartis Vaccines and Diagnostics, Inc. | Method of determining the susceptibility to bone meatastases by EPhA2 expression |
WO2005077042A2 (en) | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9737589B2 (en) | 2005-07-19 | 2017-08-22 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPs |
EP3117833A1 (en) | 2005-07-19 | 2017-01-18 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by lif |
US8460669B2 (en) | 2005-08-31 | 2013-06-11 | Academia Sinica | Compositions and methods for identifying response targets and treating flavivirus infection responses |
US7943134B2 (en) | 2005-08-31 | 2011-05-17 | Academia Sinica | Compositions and methods for identifying response targets and treating flavivirus infection responses |
EP3037544A1 (en) | 2005-10-13 | 2016-06-29 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases |
WO2007056352A2 (en) | 2005-11-07 | 2007-05-18 | The Scripps Research Institute | Compositions and methods for controlling tissue factor signaling specificity |
WO2008105797A2 (en) | 2006-06-30 | 2008-09-04 | Bristol-Myers Squibb Company | Polynucleotides encoding novel pcsk9 variants |
EP2671946A1 (en) | 2006-06-30 | 2013-12-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
EP2639301A2 (en) | 2006-06-30 | 2013-09-18 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
WO2009118300A1 (en) | 2008-03-25 | 2009-10-01 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
US9427396B2 (en) | 2008-06-27 | 2016-08-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
WO2011036118A1 (en) | 2009-09-22 | 2011-03-31 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
WO2011051392A1 (en) | 2009-10-30 | 2011-05-05 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and cancer |
WO2011107586A1 (en) | 2010-03-05 | 2011-09-09 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, | Smoc1, tenascin-c and brain cancers |
WO2011131611A1 (en) | 2010-04-19 | 2011-10-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
WO2011154485A1 (en) | 2010-06-10 | 2011-12-15 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
WO2012032143A1 (en) | 2010-09-10 | 2012-03-15 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
WO2012168259A1 (en) | 2011-06-06 | 2012-12-13 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
US9181553B2 (en) | 2011-06-06 | 2015-11-10 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Method of treatment of breast cancers over-expressing the SHP2 signature genes |
WO2013068431A1 (en) | 2011-11-08 | 2013-05-16 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
WO2013068432A1 (en) | 2011-11-08 | 2013-05-16 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
WO2013102825A1 (en) | 2012-01-02 | 2013-07-11 | Novartis Ag | Cdcp1 and breast cancer |
WO2013144240A1 (en) | 2012-03-29 | 2013-10-03 | Friedrich Miescher Institute For Biomedical Research | Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer |
WO2014001482A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research | Treating diseases by modulating a specific isoform of mkl1 |
WO2014006114A1 (en) | 2012-07-05 | 2014-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
WO2014006115A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
WO2015019286A1 (en) | 2013-08-07 | 2015-02-12 | Friedrich Miescher Institute For Biomedical Research | New screening method for the treatment friedreich's ataxia |
WO2015189816A1 (en) | 2014-06-13 | 2015-12-17 | Friedrich Miescher Institute For Biomedical Research | New treatment against influenza virus |
WO2015198202A1 (en) | 2014-06-23 | 2015-12-30 | Friedrich Miescher Institute For Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas |
WO2016001830A1 (en) | 2014-07-01 | 2016-01-07 | Friedrich Miescher Institute For Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
WO2016046768A1 (en) | 2014-09-24 | 2016-03-31 | Friedrich Miescher Institute For Biomedical Research | Lats and breast cancer |
US10583207B2 (en) | 2014-12-31 | 2020-03-10 | Lantheus Medical Imaging, Inc. | Lipid-encapsulated gas microsphere compositions and related methods |
US11395856B2 (en) | 2014-12-31 | 2022-07-26 | Lantheus Medical Imaging, Inc. | Lipid-encapsulated gas microsphere compositions and related methods |
US10022460B2 (en) | 2014-12-31 | 2018-07-17 | Lantheus Medical Imaging, Inc. | Lipid-encapsulated gas microsphere compositions and related methods |
WO2017072669A1 (en) | 2015-10-28 | 2017-05-04 | Friedrich Miescher Institute For Biomedical Research | Tenascin-w and biliary tract cancers |
US10588988B2 (en) | 2016-05-04 | 2020-03-17 | Lantheus Medical Imaging, Inc. | Methods and devices for preparation of ultrasound contrast agents |
US11344636B2 (en) | 2016-07-06 | 2022-05-31 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US11266749B2 (en) | 2016-07-06 | 2022-03-08 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US11266750B2 (en) | 2016-07-06 | 2022-03-08 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US10583208B2 (en) | 2016-07-06 | 2020-03-10 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US10220104B2 (en) | 2016-07-06 | 2019-03-05 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US9913919B2 (en) | 2016-07-06 | 2018-03-13 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US11529431B2 (en) | 2016-07-06 | 2022-12-20 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US11925695B2 (en) | 2016-07-06 | 2024-03-12 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US11857646B2 (en) | 2016-07-06 | 2024-01-02 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
US11225689B2 (en) | 2016-08-17 | 2022-01-18 | The Broad Institute, Inc. | Method for determination and identification of cell signatures and cell markers |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
US11913075B2 (en) | 2017-04-01 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
US11680296B2 (en) | 2017-10-16 | 2023-06-20 | Massachusetts Institute Of Technology | Mycobacterium tuberculosis host-pathogen interaction |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019213660A2 (en) | 2018-05-04 | 2019-11-07 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
WO2020077236A1 (en) | 2018-10-12 | 2020-04-16 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
WO2020172343A2 (en) | 2019-02-19 | 2020-08-27 | Massachusetts Institute Of Technology | Methods for treating injuries |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
WO2020186235A1 (en) | 2019-03-14 | 2020-09-17 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells |
WO2020191069A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Modulation of type 2 immunity by targeting clec-2 signaling |
WO2020191079A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2020243661A1 (en) | 2019-05-31 | 2020-12-03 | The Broad Institute, Inc. | Methods for treating metabolic disorders by targeting adcy5 |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
WO2024016003A2 (en) | 2022-07-14 | 2024-01-18 | The Broad Institute, Inc. | Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0833669B1 (en) | Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients | |
WO1996040281A9 (en) | Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients | |
JP3559849B2 (en) | Stabilized microbubble compositions for ultrasonic technology | |
KR100407755B1 (en) | Stabilized Gas Emulsion Containing Phospholipid for Ultrasound Contrast Enhancement | |
US20030138380A1 (en) | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients | |
AU731099B2 (en) | Stablized microbubble compositions for ultrasound | |
AU1759000A (en) | Gas emulsions stabilized with flourinated ethers having low Ostwald coefficients | |
MXPA97009564A (en) | Gas emulsions stabilized with fluorinated ethers having low ostwald coefficients | |
AU5775101A (en) | Stabilized microbubble compositions for ultrasound | |
MXPA97006402A (en) | Stabilized gas emulsion, containing phospholipides to increase the contrast of ultrason |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96195879.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/5-5/5,DRAWINGS,REPLACED BY NEW PAGES 1/8-8/8;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2222186 Country of ref document: CA Ref document number: 2222186 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/009564 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 1997 501477 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-3913 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970709075 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996918164 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08973281 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1996918164 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-3913 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970709075 Country of ref document: KR |
|
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996918164 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970709075 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1997-3913 Country of ref document: CZ |